Evidence map›Paper›PMID 33706413›Full record

ArticleCancer science2021

N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.

Chia-Li Han, Xuan-Ren Chen, Albert Lan, Yuan-Ling Hsu, Pei-Shan Wu, Pei-Fang Hung, Chung-Lieh Hung, Szu-Hua Pan

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Human Antibody VMolecular pharmaceutics · 2023
    Article
  16. Human Papillomavirus Infection andJournal of personalized medicine · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Chia-Li HanMaster Program in Clinical Pharmacogenomics and Pharmacoproteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Xuan-Ren ChenGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
Albert LanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yuan-Ling HsuGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
Pei-Shan WuGenome and Systems Biology Degree Program, National Taiwan University and Academia Sinica, Taipei, Taiwan.
Pei-Fang HungGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chung-Lieh HungDivision of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Szu-Hua PanGraduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-0138-0434
National Taiwan University · TWMackay Memorial Hospital · TWTaipei Medical University · TW

Funding

Ministry of Science and Technology, Taiwan 108-2314-B-002-191-MY3Ministry of Science and Technology, Taiwan 108-3114-Y-001-002Ministry of Science and Technology, Taiwan 109-2113-M-038-002Ministry of Science and Technology, Taiwan MOST 105-2628-B-002-007-MY3)National Taiwan University College of Medicine NTU-105R7879
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. As well as the identified role of epidermal growth factor receptor (EGFR), its association with driver mutations has improved the therapeutics for patients with lung cancer harboring EGFR mutations. These patients usually display shorter overall survival and a higher tendency to develop distant metastasis compared with those carrying the wild-type EGFR. Nevertheless, the way to control mutated EGFR signaling remains unclear. Here, we performed membrane proteomic analysis to determine potential components that may act with EGFR mutations to promote lung cancer malignancy. Expression of transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB) was positively correlated with the status of mutated EGFR in non-small-cell lung cancer (NSCLC). This protein was not only overexpressed but also highly glycosylated in EGFR-mutated, especially EGFR-L858R mutated, NSCLC cells. Further examination showed that GPNMB could activate mutated EGFR without ligand stimulation and could bind to the C-terminus of EGFR, assist phosphorylation at Y845, turn on downstream STAT3 signaling, and promote cancer metastasis. Moreover, we also found that Asn134 (N134) glycosylation of GPNMB played a crucial role in this ligand-independent regulation. Depleting N134-glycosylation on GPNMB could dramatically inhibit binding of GPNMB to mutated EGFR, blocking its downstream signaling, and ultimately inhibiting cancer metastasis in NSCLC. Clarifying the role of N-glycosylated GPNMB in regulating the ligand-independent activation of mutated EGFR may soon give new insight into the development of novel therapeutics for NSCLC.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementErbB ReceptorsFemaleGlycosylationHumansLigandsLung NeoplasmsMaleMembrane GlycoproteinsMembrane ProteinsMiceMice, SCIDMiddle AgedEGFR protein, humanErbB ReceptorsGPNMB protein, humanLigandsMembrane GlycoproteinsMembrane ProteinsNeoplasm ProteinsSTAT3 protein, humanSTAT3 Transcription FactorEGFR mutationGPNMBmetastasisN-glycosylationNSCLC

Identifiers

PMID33706413
PMCPMC8088973
OpenAlexW3135816555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.